KAPA Overview

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Its therapy includes antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its portfolio consists of seven drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301 and 401 and therapeutic agents ENV 105 and 205. KROS 101 is a small molecule that targets the glucocorticoid-induced tumor necrosis factor ligand-related (GITR) ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers. KROS 201 is a T cell therapy activated by dendritic cells to treat glioblastoma, a deadly and common brain cancer. ENV 105 drug seeks to address unmet medical needs in large markets of prostate and lung cancers.

Wall Street analysts forecast KAPA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KAPA is4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kairos Pharma Ltd revenue for the last quarter amounts to 0.00 USD, decreased

Kairos Pharma Ltd. EPS for the last quarter amounts to -0.07 USD, decreased -0.00

Kairos Pharma Ltd (KAPA) has 1 emplpoyees as of April 21 2026.

Today KAPA has the market capitalization of 13.59M USD.